Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease

Brain Research

Volumn 1306, Issue , 2010, Pages 176-183

  Kim, Sung Tae ^a   Son, Hyo Jin ^a   Choi, Ji Hyun ^a   Ji, In Jung ^a   Hwang, Onyou ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Dopamine; Horizontal grid test; Motor deficit; MPTP; Parkinson's disease; Vertical grid test

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DIHYDROXYPHENYLACETIC ACID; HOMOVANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GAIT; HORIZONTAL GRID TEST; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VERTICAL GRID TEST;

ANIMALIA; MUS;

EID: 71549147550     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.09.103     Document Type: Article

References (32)

1. Ambrosio S., Blesa R., Minteing G.M., Palacios-Araus L., Mahy N., and Gual A. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat. Toxicol. Lett. 44 (1988) 1-6
2. Ambrosio S., and Mahy N. Acute peripheral catecholaminergic changes in rat after MPTP and MPP+ treatment. Rev. Esp. Fisiol. 45 (1989) 157-161
3. Amende I., Kale A., McCue S., Glazier S., Morgan J.P., and Hampton T.G. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J. Neuroeng. Rehab. 2 (2005) 1-13
4. Bartolic A., Pirtosek Z., Rozman J., and Ribaric S. Postural stability of Parkinson's disease patients is improved by decreasing rigidity. Eur. J. Neurol. 12 (2005) 156-159
5. Blin O., Ferrandez A.M., and Serratrice G. Quantitative analysis of gait in Parkinson's patients: increased variability of stride length. J. Neurol. Sci. 89 (1990) 91-97
6. Castiello U., Bennett K.M.B., Bonfiglioli C., and Peppard R.F. The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication. Neuropsychologia 38 (2000) 46-59
7. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., Colebrooke R.E., Di Monte D.A., Emson P.C., and Miller G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27 (2007) 8138-8148
8. Crichton R.R., and Ward R.J. Animal models of the various neurodegenerative diseases. In: Crichton R.R., and Ward R.J. (Eds). Metal-Based Neurodegeneration (2006), John Wiley & Sons Ltd., Chichester 189-210
9. Fernagut P.O., Diguet E., Labattu B., and Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J. Neurosci. Methods 113 (2002) 123-130
10. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24 (2004) 9434-9440
11. Hong Z., Wang G., Gu J., Pan J., Bai L., Zhang S., and Chen S.D. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice. Eur. J. Neurosci. 26 (2007) 1500-1508
12. Kim S.W., Jang Y.J., Chang J.W., and Hwang O. Degeneration of the nigrostriatal pathway and induction of motor deficit by tetrahydrobiopterin: an in vivo model relevant to Parkinson's disease. Neurobiol. Dis. 13 (2003) 167-176
13. Lewis G.N., Byblon W.D., and Walt S.E. Stride length regulation in Parkinson's disease: the use of extrinsic, visual cues. Brain 123 (2000) 2077-2090
14. Matsuura K., Kabuto H., Makino H., and Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73 (1997) 45-48
15. Meredith G.E., and Kang U.J. Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov. Disord. 21 (2006) 1595-1606
16. Meredith G.E., Sonsalla P.K., and Chesselet M.F. Animal models of Parkinson's disease progression. Acta Neuropathol 115 (2008) 385-398
17. Moriss M., Iansek R., Matyas T., and Summers J. The pathogenesis of gait hypokinesia in Parkinson's disease. Brain 117 (1994) 1169-1181
18. Moriss M., Iansek R., Matyas T., and Summers J. Abnormalities in the stride length-cadence relation in parkinsonian gait. Mov. Disord. 13 (1998) 61-69
19. Muralikrishnan D., and Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J. 12 (1998) 905-912
20. Nieuwboer A., Dom R., De Weerdt W., Desloovere K., Fieuws S., and Broens-Kaucsik E. Abnormalities of the spatiotemporal characteristics of gait at the onset of freezing in Parkinson's disease. Mov. Disord. 16 (2001) 1066-1075
21. Ogawa N., Hirose Y., Oharam S., Ono T., and Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50 (1985) 435-441
22. Ogawa N., Mizukawa K., Hirose Y., Kajita S., and Watanabe Y. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur. Neurol. 26 (1987) 16-23
23. Rommelfanger K.S., Edwards G.L., Freeman K.G., Liles L.C., Miller G.W., and Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Prod. Natl. Acad. Sci. U.S.A. 104 (2007) 13804-13809
24. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., Launay J.M., Cohen-Salmon C., and Hirsch E.C. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol. Dis. 14 (2003) 218-228
25. Salarian A., Russmann H., Vingerhoets F.J., Dehollain C., Blanc Y., Burkhard P.R., and Aminian K. Gait assessment in Parkinson's disease: toward an ambulatory system for long-term monitoring. IEEE Trans. Biomed. Eng. 51 (2004) 156-159
26. Sedelis M., Hoefele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K.W. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 30 (2000) 171-182
27. Sedelis M., Schwarting R.K.W., and Hustona J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001) 109-125
28. Tillerson J.L., Caudle W.M., Reverson M.E., and Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp. Neurol. 178 (2002) 80-90
29. Tillerson J.L., and Miller G.W. Grid performance test to measure behavioral impairment in the MPTP-treated mouse model of parkinsonism. J. Neurosci. Methods 123 (2003) 189-200
30. Weihmuller F.B., Hadjiconstantinou M., and Bruno J.P. Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice. Neurosci. Lett. 85 (1988) 137-142
31. Weller C., O ' Neill C.J., Charlett A., Bowes S.G., Purkiss A., Nicholson P.W., Dobbs R.J., and Dobbs S.M. Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. Br. J. Clin. Pharmacol. 35 (1993) 379-385
32. Xu Z., Cawthon D., McCastlain K.A., Slikker Jr. W., and Ali S.F. Selective alterations of gene expression in mice induced by MPTP. Synapse 55 (2005) 45-51